| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Interim Chief Medical Officer | Chief Medical Officer
2 companies
William Grossman is Chief Medical Officer at RCUS, with reported holdings spanning 2 companies. William Grossman's net worth is not public. Form 4 filings only show shares in the companies where this person is an insider; those holdings are worth an estimated $400K at current prices.
Our model assigns William Grossman a middling insider score of 60/100, based on 4 past trades. Over a 12-month horizon, all 4 of those trades were profitable, with an average 12-month return of +12.3%.
William Grossman's largest disclosed position is in RCUS as Chief Medical Officer, worth about $392K. The RCUS filings lean toward selling, a net 14,842 shares.
William Grossman has 18 Form 4 filings on record from April 2019 to September 2026, across 3 companies: Interim Chief Medical Officer at enGene Therapeutics (ENGN), 2025–2026; Director at Day One Biopharmaceuticals (DAWN), 2024–2025; Chief Medical Officer at Arcus Biosciences (RCUS), 2019–2021.
The 29 reported transactions were 13 option or other derivative awards, 6 open-market sales, 5 open-market purchases and 3 stock awards, plus smaller numbers of other types.
Counted by filing, the open-market trades come to 3 purchases worth about $17K and 4 sales worth about $439K.
The largest open-market purchase was 5,102 shares of ENGN at an average $1.97 on September 22, 2026, about $10K.
The largest open-market sale was 7,065 shares of RCUS at an average $23.89 on June 17, 2021, about $169K. Twelve months later RCUS was down 7%.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Sep 22, 2026 | ENGN Engene Therapeutics Inc. | Interim Chief Medical Officer | Buy | 5,102 | $1.97 | $10,050.94 | New | - | - | |
| Jun 17, 2021 | RCUS Arcus Biosciences, Inc. | Chief Medical Officer | Sell | 7,065 | $23.89 | $168,808.78 | -25.4% | +40.4% | -7.4% | |
| Apr 23, 2021 | RCUS Arcus Biosciences, Inc. | Chief Medical Officer | Sell | 4,133 | $31.37 | $129,652.21 | -38.1% | -7.7% | -23.4% | |
| Mar 16, 2021 | RCUS Arcus Biosciences, Inc. | Chief Medical Officer | Sell | 2,127 | $35.03 | $74,508.60 | -16.4% | -29.8% | -4.6% | |
| Dec 16, 2020 | RCUS Arcus Biosciences, Inc. | Chief Medical Officer | Sell | 2,117 | $31.35 | $66,367.95 | -23.9% | - | - | |
| Jul 31, 2020 | RCUS Arcus Biosciences, Inc. | Chief Medical Officer | Buy | 200 | $19.72 | $3,944.56 | +50.0% | - | - | |
| Oct 14, 2019 | RCUS Arcus Biosciences, Inc. | Chief Medical Officer | Buy | 400 | $8.00 | $3,200.00 | New | - | - |